{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1870020692792607232.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/1099-1344(200008)43:9<873::aid-jlcr371>3.0.co;2-a"}},{"identifier":{"@type":"DOI","@value":"10.1002/1099-1344(200008)43:9<873::aid-jlcr371>3.3.co;2-1"}}],"dc:title":[{"@value":"Synthesis of 3-[1H-imidazol-4-yl]propyl 4-[18F]fluorobenzyl ether ([18F]fluoroproxyfan): a potential radioligand for imaging histamine H3 receptors"}],"description":[{"notation":[{"@value":"3-[1H-Imidazol-4-yl]propyl 4-fluorobenzyl ether (fluoroproxyfan), a potential histamine H 3  receptor ligand, was labeled with  18 F for clinical PET studies. The synthesis involved the O-alkylation of 3-(1-triphenylmethyl-1H-imidazol-4-yl)propanol with 4-[ 18 F]fluorobenzyl bromide in the presence of silver triflate and a non-nucleophilic amine base. 4-[18F]Fluoroproxyfan was obtained within 100 min from the end of bombardment (EOB) in 10% radiochemical yield (decay corrected to EOB) with a radiochemical purity >99% and a specific activity >150 GBq/μmol."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1890020692792607234","@type":"Researcher","foaf:name":[{"@value":"Z. Kovács"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607361","@type":"Researcher","foaf:name":[{"@value":"Tatsuo Ido"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607232","@type":"Researcher","foaf:name":[{"@value":"Géza Horváth"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607235","@type":"Researcher","foaf:name":[{"@value":"Claudio Pascali"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607236","@type":"Researcher","foaf:name":[{"@value":"Ren Iwata"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607233","@type":"Researcher","foaf:name":[{"@value":"Anna Bogni"}]},{"@id":"https://cir.nii.ac.jp/crid/1890020692792607360","@type":"Researcher","foaf:name":[{"@value":"Kazuhiko Yanai"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03624803"},{"@type":"EISSN","@value":"10991344"}],"prism:publicationName":[{"@value":"Journal of Labelled Compounds and Radiopharmaceuticals"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2000-01-01","prism:volume":"43","prism:startingPage":"873","prism:endingPage":"882"},"dataSourceIdentifier":[{"@type":"OPENAIRE","@value":"doi_dedup___::5c88e6f3150d1be20cfa2ec488ce95da"}]}